Altered Renin Release and Propranolol Potentiation of Vasodilatory Drug Hypotension

WILLIAM A. PETTINGER and KENT KEETON

From the University of Texas Southwestern Medical School, Departments of Pharmacology and Internal Medicine, Dallas, Texas 75235

ABSTRACT Vasodilating antihypertensive drugs induce hypotension with reflex tachycardia, renin release, and fluid and electrolyte retention. Propranolol can impair this renin release. The studies described here were designed to determine the hemodynamic role of vasodilatory drug-induced renin release and inhibition thereof by propranolol in two animal models, the unanesthetized, normotensive and the unanesthetized, genetically hypertensive rat. In studies with normotensive rats, the dilatory drug-induced renin release and inhibition thereof pair this drug hypotension with reflex tachycardia and fluid and electrolyte retention. Propranolol can impair this renin release. Persistence of hypotensive tachycardia after nephrectomy and after saralasin in normotensive rats suggests the irrelevance of angiotensin's central nervous system stimulation to this cardiac effect. Clinical studies are underway to quantify the potential importance of this beneficial drug interaction in man.

INTRODUCTION
When combined with propranolol, the vasodilatory drugs hydralazine and minoxidil yield an effective antihypertensive combination with few adverse effects (1-4). Vasodilatory drugs induce renin release both in man (5-7) and in animals (8), and a large portion of this renin release can be blocked by propranolol in animals (8). These studies were designed to determine if the increment in angiotensin formation resulting from an increase in serum renin activity limits vasodilatory drug hypotension, and, if so, does propranolol impairment of renin release contribute significantly to blood pressure lowering by the drug combination. After the administration of hydralazine or minoxidil, cardiovascular indices (heart rate and systolic blood pressure) were monitored in normotensive rats during three interventions: (a) propranolol impairment of renin release; (b) removal of the renin source by nephrectomy, and (c) blockade of the vasoconstrictor action of angiotensin using a new, selective angiotensin antagonist, saralasin (1-Sar-8-Ala-angiotensin II). In addition mean arterial pressure was monitored in genetically hypertensive rats after treatment with propranolol, hydralazine, saralasin, propranolol plus hydralazine, and saralasin plus hydralazine.

METHODS
Normotensive, male Wistar (Simonsen Laboratories, Gilroy, Calif.) or genetically hypertensive (16-22 wk, Okamoto strain, Taconic Farms, Inc., Germantown, N. Y.) rats, weighing 180-250 g, were housed individually and exposed to a 16-h light-dark cycle with free access to food and water. All rats were pretreated with a new, selective angiotensin antagonist, saralasin (1-Sar-8-Ala-angiotensin II). In addition mean arterial pressure was monitored in genetically hypertensive rats after treatment with propranolol, hydralazine, saralasin, propranolol plus hydralazine, and saralasin plus hydralazine.

Received for publication 3 August 1974 and in revised form 26 September 1974.
The Blockade of Hydralazine-Induced Renin Release by Propranolol in the Genetically Hypertensive Rat

<table>
<thead>
<tr>
<th></th>
<th>SRA* (X±SEM) (n = 7)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saline control</td>
<td>2.54±0.24</td>
</tr>
<tr>
<td>Hydralazine</td>
<td>11.15±0.82</td>
</tr>
<tr>
<td>(1.0 mg/kg)</td>
<td></td>
</tr>
<tr>
<td>Propranolol +</td>
<td>2.96±0.21</td>
</tr>
<tr>
<td>hydralazine</td>
<td></td>
</tr>
<tr>
<td>(1.5 mg/kg)</td>
<td></td>
</tr>
<tr>
<td>(1.0 mg/kg)</td>
<td></td>
</tr>
</tbody>
</table>

* SRA = nanograms A1 per milliliter serum per hour at 37°C.

RESULTS

Biochemical studies with normotensive rats. Characteristics of vasodilatory drug-induced renin release and the effect of propranolol on this mechanism of renin release are summarized in Figs. 1 and 2. Fig. 1 gives the chronology of renin release by minoxidil and hydralazine as well as the log dose-response curve for the two drugs. Parts of these data were reported previously (8) and are extended and summarized here for ready comparison with hemodynamic events. The ability of different doses of propranolol to impair renin release caused by these two vasodilators are shown in Fig. 2. Here these data are not reported as actual SRA but rather as the percent inhibition by propranolol of increases in SRA from control values caused by the drugs.

Abbreviations used in this paper: MAP, mean arterial pressure; SRA, serum renin activity.

Figure 1 Dose response and chronology of hydralazine and minoxidil-induced renin release in normotensive rats. Blood for SRA was collected 20 min (hydralazine) and 40 min (minoxidil) after i.p. administration in the dose-response experiments. Each value is the mean±SEM for six animals.

Renin and Vasodilatory Drug Hypotension 237

References:

minoxidil and hydralazine. Propranolol in a dose resulting in plasma levels below 20 ng/ml, impaired 50% of minoxidil (1.0 mg/kg)- and hydralazine (1.0 mg/kg)-induced renin release. 0.3 and 1.5 mg/kg propranolol gave plasma levels of 49±4 and 222±19 ng/ml, respectively (8) and gave maximal impairment of hydralazine- and minoxidil-induced renin release. A high dose of propranolol (15.0 mg/kg) giving plasma concentrations of 750±98 ng/ml resulted in less impairment of renin release than lower propranolol doses. Also higher (3.0 and 10 mg/kg) minoxidil and hydralazine doses were capable of overriding propranolol's (1.5 mg/kg) inhibition of renal release.

Hemodynamic studies with normotensive rats. 1 mg/kg hydralazine (which results in a sevenfold increase in SRA) lowered average systolic blood pressure by 21% and markedly increased the heart rate (Fig. 3). In the same rats propranolol (1.5 mg/kg) lowered blood
FIGURE 6 Hemodynamic changes following minoxidil; propranolol and minoxidil and minoxidil after nephrectomy (18 h previously) in normotensive rats. Propranolol (1.5 mg/kg) was given s.c. 10 min before minoxidil (1.0 mg/kg) i.p. Each value is the mean±SEM for six animals. Statistical tests for blood pressure measurements (*) are a comparison of minoxidil treatment alone vs. propranolol and minoxidil or nephrectomy and minoxidil. Propranolol and minoxidil treatment is also compared (**) with nephrectomy and minoxidil. Statistical comparisons for heart rate measurements (***) are a comparison of propranolol and minoxidil treatment with minoxidil treatment or nephrectomy and minoxidil.

pressure by 5% and heart rate by 13%. Combined treatment with propranolol and hydralazine lowered blood pressure by an average of 39% and mitigated the tachycardia caused by hydralazine alone.

Results of hemodynamic studies with the combination of minoxidil and propranolol (Fig. 4) are similar except for the prolonged duration of action with minoxidil. Propranolol and minoxidil reduced blood pressure by 3 and 15%, respectively whereas propranolol decreased the heart rate and minoxidil, when given alone, markedly increased the heart rate. Again propranolol significantly (P < 0.05) potentiated minoxidil hypotension (24% decrement in blood pressure) and prevented the associated tachycardia.

Removal of the source of renin by nephrectomy potentiated hydralazine- (Fig. 5) and particularly minoxidil- (Fig. 6) induced hypotension. However, nephrectomy did not alter the tachycardia caused by either vasodilator. The hydralazine hypotension after nephrectomy (43%) was comparable to that with the combination of propranolol and hydralazine (39%). Minoxidil (41%) and hydralazine (39%) hypotension after nephrectomy were comparable, but the blood pressure lowering with the minoxidil-propranolol combination (24%) was only about one-half that of minoxidil and nephrectomy.

FIGURE 7 Saralasin potentiation of hydralazine hypotension in normotensive rats. Saralasin (10 mg/kg) was given s.c. 20 min before hydralazine (1.0 mg/kg) i.p. Each value is the mean±SEM for six animals.

Blockade of the vasoconstrictor effects of angiotensin with the selective angiotensin antagonist saralasin resulted in potentiation of hydralazine (Fig. 7) and minoxidil (Fig. 8) hypotension. Further studies were done in another group of rats to determine whether the effect of propranolol was additive to that of saralasin in potentiating hydralazine hypotension. The results in Fig. 9 show that saralasin (10 mg/kg) alone had no effect on blood pressure or heart rate. Again, hydralazine lowered blood pressure (10%) with a concomitant increase in heart rate. This hypotension was potentiated with propranolol (18%) which also blocked the tachycardia. Saralasin and hydralazine caused a greater decrease in blood pressure (26%) than the propranolol-hydralazine combination, and the tachycardia pattern was similar to

FIGURE 8 Saralasin potentiation of minoxidil hypotension in normotensive rats. Saralasin (10 mg/kg) was given s.c. 20 min before minoxidil (1.0 mg/kg) i.p. Each value is the mean±SEM for six animals.

Renin and Vasodilatory Drug Hypotension 239
that of hydralazine alone. Pretreatment with both saralasin and propranolol before hydralazine did not cause greater blood pressure lowering (25%) than with saralasin pretreatment alone. The smaller percent decrease in blood pressure with hydralazine noted here compared with Fig. 3 appears to be due to biological variation between groups of rats as in patients. This is the reason that each rat was used as its own control in each group of experiments.

Biochemical studies with genetically hypertensive rats. The same pattern of blockade of hydralazine-induced renin release as seen in the normotensive rat (8) was observed in the genetically hypertensive rat (Table I). Hydralazine (1 mg/kg) resulted in a fourfold increase in SRA, and propranolol pretreatment (1.5 mg/kg) blocked 95% of this increase.

Hemodynamic studies with genetically hypertensive rats. Results similar to those obtained with the normotensive (Fig. 9) rats were observed when the same drug combinations were administered to genetically hypertensive rats (Fig. 10). In the latter case, hydralazine (1 mg/kg) caused a 17% decrease in mean arterial pressure (MAP) whereas propranolol had an initial pressor effect (10.2%) which was followed by a gradual decrease in blood pressure (3.2% at 60 min).

![Figure 9](image9.png)

**Figure 9** Hemodynamic changes hydralazine; saralasin; saralasin and hydralazine; propranolol and hydralazine; and saralasin, propranolol and hydralazine in normotensive rats. Propranolol (1.5 mg/kg) was given s.c. 10 min and (10 mg/kg) 20 min before hydralazine (1.0 mg/kg) i.p. Statistical tests for blood pressure measurements are a comparison of hydralazine treatment with propranolol and hydralazine; saralasin and hydralazine; and propranolol, saralasin, and hydralazine treatments. Statistical tests for heart rate measurements are a comparison of propranolol and hydralazine treatment with hydralazine; saralasin and hydralazine; and propranolol, saralasin, and hydralazine treatments.

![Figure 10](image10.png)

**Figure 10** Hemodynamic changes following hydralazine; saralasin; saralasin and hydralazine; propranolol; and propranolol and hydralazine in genetically hypertensive rats. Propranolol (1.0 mg/kg) was given s.c. 10 min before hydralazine (1.0 mg/kg) i.p. Saralasin (10 mg/kg) was given s.c. 20 min before hydralazine (1.0 mg/kg) i.p. Statistical tests (*) are a comparison of hydralazine treatments with propranolol and hydralazine treatment or saralasin and hydralazine treatment. Propranolol and hydralazine treatment are also compared (') with saralasin and hydralazine treatment.

Saralasin alone (10 mg/kg) caused a significant decrement (7.4%) in blood pressure at one time period (55 min). When the rats were pretreated with propranolol and then given hydralazine, propranolol significantly potentiated (28.9% blood pressure decrease) the hypotension elicited by hydralazine. Saralasin pretreatment initially potentiated hydralazine hypotension more than propranolol, but after 35 min there was no significant difference between propranolol plus hydralazine (28.9%) and salaspin plus hydralazine (34.3%) despite the fact that the saralasin-hydralazine averages were less (approximately 10 mm Hg) than those of propranolol-hydralazine treatment.

Heart rate was not recorded during the different drug treatments since MAP was being measured in the genetically hypertensive rat.

**DISCUSSION**

Angiotensin has multiple sites of pharmacologic action including central nervous system-mediated cardiac stimulation (11–13), sympathetic neuronal activation (14–17), and the well-known vascular and adrenal effects. Each of these pharmacologic actions contributes qualitatively to blood pressure elevation. The increment in SRA caused by vasodilating drugs significantly increases the levels of circulating angiotensin (18). This increment would be expected to antagonize or limit the hypotensive action of vasodilating drugs due to angiotensin's broad spectrum of activities as well as the dynamic relationship between angiotensin and vasodilators at the vascular smooth muscle sites of action (19).
In these experiments with normotensive rats, impairment of renin release by propranolol was associated with marked potentiation of vasodilatory drug-induced hypotension. This observation is consistent with the hypothesis that increased angiotensin levels limit the effectiveness of systemic vasodilators, but it should be kept in mind that propranolol also blocks reflex cardiac stimulation. It has been suggested that the antihypertensive activity of propranolol alone may result from reduced cardiac output (20), but this mechanism of action has been criticized (21). Since we did not measure cardiac outputs in these experiments, the possibility that this potentiation by propranolol is due in part to its negative inotropic and chronotropic cardiac effects cannot be eliminated. Propranolol also may contribute by a central nervous system mechanism (22-24) to blood pressure reduction. Although propranolol accentuated the hypotension following both vasodilators, the potentiation due to hydralazine appeared to be more pronounced than that due to minoxidil. It is unknown whether this observation is related to chronologic differences in blood pressure depression and renin release by the two agents.

Removal of the renin source by prior bilateral nephrectomy resulted in marked potentiation of hydralazine- and minoxidil-induced hypotension. This remarkable potentiation is consistent with the idea that the increment in angiotensin formed from elevated SRA antagonized a major component of the hypotensive activity of the vasodilating drugs. Absence of urinary excretion of hydralazine (25), and minoxidil (26), however, could also contribute to this enhanced activity.

The marked tachycardia remaining after nephrectomy suggests that the cardiac stimulation precipitated by these vasodilating drugs is not dependent on angiotensin-mediated central nervous system effects since the renin source is absent. This result also implies that blockade of the cardiac stimulation by propranolol is not the major potentiating mechanism of propranolol to the blood pressure decrement since this decrement occurred in presence of the tachycardia in nephrectomized animals.

Since propranolol can block both inotropic and chronotropic responses and since there is the possibility for error resulting from altered drug excretion following nephrectomy, our hypothesis was tested more specifically by using the selective angiotensin antagonist, saralasin (27). Saralasin potentiated hydralazine hypotension without altering the pattern of cardiac stimulation. Additionally, impairment of renin release with propranolol pretreatment did not induce blood pressure-lowering greater than the pretreatment with saralasin. The greater efficacy of saralasin pretreatment is no doubt due to the fact that it is competitively blocking the smooth muscle receptor for angiotensin. Even though propranolol is quite efficient in blocking renin release with hydralazine (91% at this propranolol dose, see reference 8), the small increment in angiotensin remaining may express some pharmacologic activity. Thus, it is not surprising that a combined pretreatment with saralasin and propranolol could not potentiate hydralazine hypotension more than saralasin pretreatment alone.

Persistence of vasodilatory drug-induced tachycardia in nephrectomized and in saralasin-pretreated animals indicates that the cardiac stimulation is not dependent on central nervous system effects of angiotensin. A possible explanation is that saralasin did not have access to, or was ineffective in blocking an angiotensin receptor in the brain. However, this possibility seems unlikely since a peptide pharmacologically similar (1-Sar-8-Ile-angiotensin II) to saralasin has previously been shown to block centrally mediated angiotensin stimulation in dogs (28) when angiotensin was administered from an exogenous source. In addition, studies of Pals and Fulton (29) provide evidence that the antihypertensive activity of saralasin in the acute phase of unilateral renal hypertension in rats was due in part to an antagonism of central nervous interactions of angiotensin II.

Brunner, Hedwall, and Meier (30) previously reported no potentiation of hydralazine hypotension in normotensive rats by propranolol. However, hydralazine was administered intravenously instead of intraperitoneally and the effect monitored for only 30 min. Since a dynamic relationship exists between angiotensin and vasodilating drugs at the vascular smooth muscle site (19), the acute high plasma concentrations of hydralazine resulting from intravenous administration may have dominated angiotensin's effect to such an extent that no potentiation would be expected from propranolol during the brief interval of observation.

Qualitatively similar results were obtained in biochemical (Table I) and hemodynamic (Fig. 10) studies with genetically hypertensive rats. Propranolol, in a dose known to cause a 20-fold displacement to the right of the isoproterenol (tachycardia) dose-response curve in normotensive rats (8), blocked 95% of the renin release elicited by hydralazine (Table I) in the genetically hypertensive rat. In the normotensive rat, this dose of propranolol impaired 91% of the hydralazine-induced rise in SRA (8). Thus the impairment of vasodilatory drug-induced renin release is essentially the same in normotensive and genetically hypertensive rats.

If the results of the hemodynamic experiments with normotensive (Fig. 9) and genetically hypertensive (Fig. 10) rats are compared, a similar pattern of blood pressure decrement and potentiation was observed when propranolol or saralasin treatment preceded hydralazine.

Scriabine, Ludden, and Bohidar (31) recently re-

Renin and Vasodilatory Drug Hypotension 241
ported potentiation of hydralazine hypotension using the beta adrenergic-blocking drug timolol, but failed to show similar potentiation by propranolol, in the genetically hypertensive rat. However, there were important technical differences from the studies reported here. Propranolol and hydralazine were administered orally in their studies. Both drugs are rapidly metabolized in the liver, particularly with the first dose or with low portal venous concentrations (32, 33). This technical difference could explain the variable presence of tachycardia in their hydralazine controls. In our experiments propranolol was administered subcutaneously, and effectiveness of the beta adrenergic blockade was confirmed along with measurements of propranolol blood levels (8). Also, we administered hydralazine parenterally and found rapid and consistent effects on blood pressure and heart rate. Alternatively, Scriabine, Ludden, and Bohidar (31) reported only the maximal blood pressure decrement noted during a 24-h period. These technical differences may have resulted in their failure to demonstrate propranolol's potentiating effect.

A major side effect of treatment with antihypertensive vasodilators is reflex sympathetic stimulation resulting in increased heart rate and cardiac output (1–4). Propranolol was originally combined with vasodilators (it was known to possess some antihypertensive activity of its own [22, 34, 35]) to mitigate these untoward effects, but even greater benefit was gained from the combined drug treatment since the hypotensive efficacy of the vasodilator was increased (1). Bühler, Laragh, Baer, Vaughn, and Brunner’s (36) recent evidence that suppression of renin release with propranolol correlated with the hypotensive effect of propranolol alone, is consistent with the thesis that potentiation of vasodilator drug hypotension by propranolol may operate via this mechanism.

ACKNOWLEDGMENTS

We are indebted to Dr. Castellion of Norwich Pharmacal for the saralasin (P-113) and the gelatin formulation. The authors would like to thank Martha Williams for her technical assistance and Linda Moscattelli for her secretarial assistance.

This work was supported in part by the Texas Heart Association, Merck Foundation, and the Norwich Pharmacal Company.

REFERENCES


